サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1500798

舌下アレルギー免疫療法市場：世界の産業分析、規模、シェア、成長、動向、予測、2024～2033年

Sublingual Allergy Immunotherapy Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2033
出版日: | 発行: Persistence Market Research | ページ情報: 英文 258 Pages | 納期: 2～5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.25円
舌下アレルギー免疫療法市場：世界の産業分析、規模、シェア、成長、動向、予測、2024～2033年
出版日: 2024年06月18日
発行: Persistence Market Research
ページ情報: 英文 258 Pages
納期: 2～5営業日
  • 全表示
  • 概要
  • 目次
概要

Persistence Market Researchはこのほど、舌下アレルギー免疫療法（SLIT）市場に関する包括的なレポートを発表しました。当レポートでは、市場促進要因・動向・機会・課題などの主要な市場力学を詳細に評価し、市場構造に関する洞察を提供しています。この調査レポートは、2024～2033年までの世界の舌下アレルギー免疫療法市場の予測成長軌道を概説する独占データと統計を掲載しています。

主要洞察

  • 舌下アレルギー免疫療法の市場規模（2024年）：4億6,870万米ドル
  • 予測市場規模（2033年）：10億2,000万米ドル
  • 世界市場成長率（CAGR 2024～2033年）：9.0%

舌下アレルギー免疫療法市場：調査範囲

舌下アレルギー免疫療法は、舌下にアレルゲンを投与して特定のアレルゲンに感作させるもので、アレルギー性鼻炎やアレルギー性喘息などのアレルギー疾患に対して非侵襲的な治療法を記載しています。同市場は、アレルギー専門医、免疫専門医、耳鼻咽喉科専門医を対象としており、個々の患者プロファイルに合わせたアレルゲン抽出物や治療レジメンを幅広く提供しています。市場成長の原動力は、アレルギーの有病率の増加、患者の意識の高まり、治療プロトコルの進歩による治療効果と患者のコンプライアンスの向上です。

市場促進要因：

世界の舌下アレルギー免疫療法市場は、世界のアレルギー疾患の有病率の上昇、個別化医療アプローチに対する需要の増加、アレルギー免疫療法治療を支援する有利な規制状況など、いくつかの主要要因により推進されています。アレルゲンエキスの製剤や投与技術における技術の進歩が、市場拡大にさらに寄与しています。さらに、精密医療と患者中心の医療モデルへのシフトは、市場参入企業に新たな成長機会をもたらしています。

市場抑制要因：

有望な成長展望にもかかわらず、舌下アレルギー免疫療法市場は、償還政策、治療結果のばらつき、アレルゲンエキスの製造と流通を管理する規制の複雑さに関する課題に直面しています。地域によってはアレルギー免疫療法に対する保険適用が限定的であること、治療開始に伴う初期費用が高額であることなどが、特に新興国において市場導入の障壁となっています。

市場機会：

舌下アレルギー免疫療法市場は、アレルゲンエキスの標準化の進展、呼吸器アレルギー以外の適応の拡大、第一選択薬としての舌下免疫療法の採用拡大などにより、大きな成長機会をもたらしています。製薬企業、研究機関、医療プロバイダーが協力して新規アレルゲン製剤や治療プロトコルを開発することは、新たな機会を活用し、市場参入を拡大するために不可欠です。

本レポートで扱う主要質問

  • 舌下アレルギー免疫療法市場の世界的成長を促進する主要要因は何か？
  • どのようなアレルゲンタイプと治療プロトコールが、さまざまな患者集団での採用を促進しているか？
  • 技術進歩は舌下アレルギー免疫療法市場の競合情勢をどのように変えているか？
  • 舌下アレルギー免疫療法市場に貢献している主要参入企業は誰で、市場の関連性を維持するためにどのような戦略を採用しているのか？
  • 世界の舌下アレルギー免疫療法市場における新たな動向と将来展望は？

目次

第1章 エグゼクティブ概要

第2章 市場概要

  • 市場範囲/ 分類
  • 市場の定義/ 範囲/ 制限
  • 包含と除外

第3章 主要な市場動向

  • 市場に影響を与える主要動向
  • 製品イノベーション/開発動向

第4章 付加価値の洞察

  • 地域別の主要適応症の疫学
  • 製品の採用/使用状況分析
  • パイプライン評価
  • 規制シナリオ
  • 償還の情勢
  • PESTLE分析
  • PORTER分析
  • 最新の業界取引/M&A

第5章 世界市場の需要分析

  • 過去の市場数量（個）分析、2019～2023年
  • 現在と将来の市場規模（個）予測、2024～2033年
    • 前年比成長動向分析

第6章 世界市場-価格分析

  • 薬剤別の地域別価格分析
  • 世界平均価格分析ベンチマーク
  • 価格設定の前提

第7章 世界市場の需要（金額または規模、100万米ドル）分析

  • 過去の市場金額（100万米ドル）分析、2019～2023年
  • 現在と将来の市場金額（100万米ドル）予測、2024～2033年
    • 前年比成長動向分析
    • 絶対金額機会分析

第8章 市場背景

  • マクロ経済要因
  • 予測要因-関連性と影響
  • 市場力学

第9章 医薬品別の世界の市場分析

  • イントロダクション/主要調査結果
  • 過去の市場規模（100万米ドル）動向分析、医薬品別、2019～2023年
  • 現在と将来の市場規模（100万米ドル）の分析と予測、医薬品別、2024～2033年
    • オダクトラ
    • グラステック
    • ラグウィテック
    • オラエア
    • アクティア
    • その他
  • 医薬品別市場の魅力分析

第10章 症状別の世界の市場分析

  • イントロダクション/主要調査結果
  • 過去の市場規模（100万米ドル）動向分析、症状別、2019～2023年
  • 現在と将来の市場規模（100万米ドル）の分析と予測、症状別、2024～2033年
    • アレルギー性鼻炎
    • アレルギー性喘息
    • 食物アレルギー
    • アトピー性皮膚炎
    • その他
  • 症状別の市場の魅力分析

第11章 アラガンタイプ別の世界の市場分析

  • イントロダクション/主要調査結果
  • 過去の市場規模（100万米ドル）動向分析、アラガンタイプ別、2019～2023年
  • 現在と将来の市場規模（100万米ドル）の分析と予測、アラガンタイプ別、2024～2033年
    • 花粉末
    • ハウスダストダニ（HDM）
    • 型
    • 動物の鱗屑
    • 蜂毒
    • ゴキブリ/昆虫
    • その他
  • アラガンタイプ別市場の魅力分析

第12章 流通チャネル別の世界の市場分析

  • イントロダクション/主要調査結果
  • 過去の市場規模（100万米ドル）動向分析、流通チャネル別、2019～2023年
  • 現在と将来の市場規模（100万米ドル）の分析と予測、流通チャネル別、2024～2033年
    • 機関投資家向け販売
      • 政府病院
      • 準政府病院
      • 私立病院
    • 小売売上高
      • 小売薬局
      • ドラッグストア
      • オンライン薬局
  • 流通チャネル別市場の魅力分析

第13章 地域別の世界の市場分析

  • イントロダクション
  • 過去の市場規模（100万米ドル）動向分析、地域別、2019～2023年
  • 現在と将来の市場規模（100万米ドル）の分析と予測、地域別、2024～2033年
    • 北米
    • ラテンアメリカ
    • 欧州
    • 東アジア
    • 南アジア
    • オセアニア
    • 中東・アフリカ
  • 地域別市場の魅力分析

第14章 北米市場分析

第15章 ラテンアメリカ市場分析

第16章 欧州市場分析

第17章 東アジア市場分析

第18章 南アジア市場分析

第19章 オセアニア市場

第20章 中東・アフリカ市場分析

第21章 市場構造分析

  • 企業階層別市場分析
  • 主要企業の市場シェア分析
  • 市場集中
  • 市場プレゼンス分析

第22章 競合分析

  • 競合ダッシュボード
  • 主要参入企業によるブランディングとプロモーション戦略
  • 主要開発分析
  • 競合の詳細
    • ALK Abello
    • Stallergenes Greer
    • Allergy Therapeutics
    • Aimmune Therapeutics
    • Biomay AG
    • HAL Allergy group
    • DBV Technologies
    • Merck KGaA
    • WOLWpharma

第23章 使用される仮定と頭字語

第24章 調査手法

目次
Product Code: PMRREP14968

Persistence Market Research has recently released a comprehensive report on the Sublingual Allergy Immunotherapy (SLIT) market. The report provides a detailed assessment of key market dynamics, including drivers, trends, opportunities, and challenges, offering insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global Sublingual Allergy Immunotherapy market from 2024 to 2033.

Key Insights:

  • Sublingual Allergy Immunotherapy Market Size (2024E): USD 468.7 Million
  • Projected Market Value (2033F): USD 1020 Million
  • Global Market Growth Rate (CAGR 2024 to 2033): 9.0%

Sublingual Allergy Immunotherapy Market - Report Scope:

Sublingual Allergy Immunotherapy involves the administration of allergens under the tongue to desensitize patients to specific allergens, offering a non-invasive treatment option for allergic conditions such as allergic rhinitis and allergic asthma. The market caters to allergists, immunologists, and ENT specialists, providing a range of allergen extracts and treatment regimens tailored to individual patient profiles. Market growth is driven by increasing prevalence of allergies, growing patient awareness, and advancements in treatment protocols, enhancing treatment efficacy and patient compliance.

Market Growth Drivers:

The global Sublingual Allergy Immunotherapy market is propelled by several key factors, including rising prevalence of allergic disorders worldwide, increasing demand for personalized medicine approaches, and favorable regulatory landscape supporting allergy immunotherapy treatments. Technological advancements in allergen extract formulations and administration techniques are further contributing to market expansion. Moreover, the shift towards precision medicine and patient-centric healthcare models is creating new growth opportunities for market players.

Market Restraints:

Despite promising growth prospects, the Sublingual Allergy Immunotherapy market faces challenges related to reimbursement policies, variability in treatment outcomes, and regulatory complexities governing allergen extract manufacturing and distribution. Limited insurance coverage for allergy immunotherapy treatments in some regions and high upfront costs associated with treatment initiation pose barriers to market adoption, particularly in emerging economies.

Market Opportunities:

The Sublingual Allergy Immunotherapy market presents significant growth opportunities driven by advancements in allergen extract standardization, expansion of indications beyond respiratory allergies, and increasing adoption of sublingual immunotherapy as a first-line treatment option. Collaborations between pharmaceutical companies, research institutions, and healthcare providers to develop novel allergen formulations and treatment protocols are critical to capitalize on emerging opportunities and expand market reach.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the Sublingual Allergy Immunotherapy market globally?
  • Which allergen types and treatment protocols are driving adoption across different patient populations?
  • How are technological advancements reshaping the competitive landscape of the Sublingual Allergy Immunotherapy market?
  • Who are the key players contributing to the Sublingual Allergy Immunotherapy market, and what strategies are they employing to maintain market relevance?
  • What are the emerging trends and future prospects in the global Sublingual Allergy Immunotherapy market?

Competitive Intelligence and Business Strategy:

Leading players in the global Sublingual Allergy Immunotherapy market, including XYZ Pharmaceuticals, ABC Biotech, and PQR Allergen Solutions, focus on innovation, clinical research, and strategic partnerships to gain a competitive edge. These companies invest in R&D to enhance allergen extract efficacy, develop novel delivery systems, and expand market presence through geographic expansion and product diversification. Collaboration with healthcare providers and patient advocacy groups facilitates market access and promotes adoption of Sublingual Allergy Immunotherapy as a preferred allergy treatment option.

Key Companies Profiled:

  • ALK Abello
  • Stallergenes Greer
  • Allergy Therapeutics
  • Aimmune Therapeutics
  • Merck
  • Biomay AG
  • HAL Allergy Group
  • DBV Technologies
  • Merck KgaA
  • WOLWpharma

Key Segments of SLIT Industry Research

Drug:

  • Odactra
  • Grastek
  • Ragwitek
  • Oralair
  • Actair
  • Others

Indication:

  • Allergic Rhinitis
  • Allergic Asthma
  • Food Allergy
  • Atopic Dermatitis
  • Others

Allergen:

  • Pollen
  • House Dust Mites
  • Mold
  • Animal Dander
  • Bee Venom
  • Cockroaches/Insects
  • Others

Distribution Channel:

  • Institutional Sales
  • Retail Sales

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Supply Side Trends
  • 1.4. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations
  • 2.3. Inclusions and Exclusions

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Product Innovation / Development Trends

4. Value Added Insights

  • 4.1. Epidemiology of Key Indication, By Region
  • 4.2. Product Adoption/Usage Analysis
  • 4.3. Pipeline Assessment
  • 4.4. Regulatory Scenario
  • 4.5. Reimbursement Landscape
  • 4.6. PESTLE Analysis
  • 4.7. PORTER Analysis
  • 4.8. Latest Industry Deals/M&A

5. Global Market Demand Analysis 2019-2023 and Forecast, 2024-2033

  • 5.1. Historical Market Volume (Units) Analysis, 2019-2023
  • 5.2. Current and Future Market Volume (Units) Projections, 2024-2033
    • 5.2.1. Y-o-Y Growth Trend Analysis

6. Global Market - Pricing Analysis

  • 6.1. Regional Pricing Analysis By Drug
  • 6.2. Global Average Pricing Analysis Benchmark
  • 6.3. Pricing Assumptions

7. Global Market Demand (in Value or Size in US$ Mn) Analysis 2019-2023 and Forecast, 2024-2033

  • 7.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
  • 7.2. Current and Future Market Value (US$ Mn) Projections, 2024-2033
    • 7.2.1. Y-o-Y Growth Trend Analysis
    • 7.2.2. Absolute $ Opportunity Analysis

8. Market Background

  • 8.1. Macro-Economic Factors
    • 8.1.1. Global GDP Growth Outlook
    • 8.1.2. Global Healthcare GDP Growth Overview
    • 8.1.3. Global Geriatric Population
    • 8.1.4. Global R&D Funding and Infrastructure Investment
    • 8.1.5. Global Allergy Immunotherapy Market Overview
  • 8.2. Forecast Factors - Relevance & Impact
    • 8.2.1. Rising Prevalence Asthma.
    • 8.2.2. Increasing Awareness for food allergy.
    • 8.2.3. Increasing Healthcare Spending.
    • 8.2.4. Rising focus on strengthening of immune system
    • 8.2.5. Rising geriatric population
    • 8.2.6. Rise In industrialization in regions
    • 8.2.7. Rise of population due to industrial waste
    • 8.2.8. Research and development in immunotherapeutic drugs.
  • 8.3. Market Dynamics
    • 8.3.1. Drivers
    • 8.3.2. Restraints
    • 8.3.3. Opportunity Analysis

9. Global Market Analysis 2019-2023 and Forecast 2024-2033, by Drug

  • 9.1. Introduction / Key Findings
  • 9.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Drug, 2019-2023
  • 9.3. Current and Future Market Size (US$ Mn) and Volume (Units) and Trend Analysis and Forecast By Drug, 2024-2033
    • 9.3.1. ODACTRA
    • 9.3.2. GRASTEK
    • 9.3.3. RAGWITEK
    • 9.3.4. ORALAIR
    • 9.3.5. ACTAIR
    • 9.3.6. Others
  • 9.4. Market Attractiveness Analysis By Drug

10. Global Market Analysis 2019-2023 and Forecast 2024-2033, by Indication

  • 10.1. Introduction / Key Findings
  • 10.2. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2019-2023
  • 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Indication, 2024-2033
    • 10.3.1. Allergic Rhinitis
    • 10.3.2. Allergic Asthma
    • 10.3.3. Food Allergy
    • 10.3.4. Atopic Dermatitis
    • 10.3.5. Others
  • 10.4. Market Attractiveness Analysis By Indication

11. Global Market Analysis 2019-2023 and Forecast 2024-2033, by Allergan Type

  • 11.1. Introduction / Key Findings
  • 11.2. Historical Market Size (US$ Mn) Trend Analysis By Allergan Type, 2019-2023
  • 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Allergan Type, 2024-2033
    • 11.3.1. Pollens
    • 11.3.2. House Dust Mites (HDM)
    • 11.3.3. Mould
    • 11.3.4. Animal Dander
    • 11.3.5. Bee Venom
    • 11.3.6. Cockroaches/Insects
    • 11.3.7. Others
  • 11.4. Market Attractiveness Analysis By Allergan Type

12. Global Market Analysis 2019-2023 and Forecast 2024-2033, by Distribution Channel

  • 12.1. Introduction / Key Findings
  • 12.2. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2019-2023
  • 12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2024-2033
    • 12.3.1. Institutional Sales
      • 12.3.1.1. Gov. Hospitals
      • 12.3.1.2. Semi-Gov. Hospitals
      • 12.3.1.3. Private Hospitals
    • 12.3.2. Retail Sales
      • 12.3.2.1. Retail Pharmacy
      • 12.3.2.2. Drug Stores
      • 12.3.2.3. Online Pharmacy
  • 12.4. Market Attractiveness Analysis By Distribution Channel

13. Global Market Analysis 2019-2023 and Forecast 2024-2033, by Region

  • 13.1. Introduction
  • 13.2. Historical Market Size (US$ Mn) Trend Analysis By Region, 2019-2023
  • 13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2024-2033
    • 13.3.1. North America
    • 13.3.2. Latin America
    • 13.3.3. Europe
    • 13.3.4. East Asia
    • 13.3.5. South Asia
    • 13.3.6. Oceania
    • 13.3.7. Middle East and Africa (MEA)
  • 13.4. Market Attractiveness Analysis By Region

14. North America Market Analysis 2019-2023 and Forecast 2024-2033

  • 14.1. Introduction
  • 14.2. Historical Market Size (US$ Mn) and Volume (Units) Trend Analysis By Market Taxonomy, 2019-2023
  • 14.3. Current and Future Market Size (US$ Mn) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2024-2033
    • 14.3.1. By Country
      • 14.3.1.1. U.S.
      • 14.3.1.2. Canada
    • 14.3.2. By Drug
    • 14.3.3. By Indication
    • 14.3.4. By Allergan Type
    • 14.3.5. By Distribution Channel
  • 14.4. Market Attractiveness Analysis
    • 14.4.1. By Country
    • 14.4.2. By Drug
    • 14.4.3. By Indication
    • 14.4.4. By Allergan Type
    • 14.4.5. By Distribution Channel
  • 14.5. Market Trends
  • 14.6. Drivers and Restraints - Impact Analysis
  • 14.7. Key Market Participants - Intensity Mapping
  • 14.8. Country Level Analysis & Forecast
    • 14.8.1. U.S. Market Analysis
      • 14.8.1.1. .Introduction
      • 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.1.2.1. By Drug
        • 14.8.1.2.2. By Indication
        • 14.8.1.2.3. By Allergan Type
        • 14.8.1.2.4. By Distribution Channel
    • 14.8.2. Canada Market Analysis
      • 14.8.2.1. Introduction
      • 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.2.2.1. By Drug
        • 14.8.2.2.2. By Indication
        • 14.8.2.2.3. By Allergan Type
        • 14.8.2.2.4. By Distribution Channel

15. Latin America Market Analysis 2019-2023 and Forecast 2024-2033

  • 15.1. Introduction
  • 15.2. Historical Market Size (US$ Mn) and Volume (Units) Trend Analysis By Market Taxonomy, 2019-2023
  • 15.3. Current and Future Market Size (US$ Mn) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2024-2033
    • 15.3.1. By Country
      • 15.3.1.1. Mexico
      • 15.3.1.2. Brazil
      • 15.3.1.3. Argentina
      • 15.3.1.4. Rest of Latin America
    • 15.3.2. By Drug
    • 15.3.3. By Indication
    • 15.3.4. By Allergan Type
    • 15.3.5. By Distribution Channel
  • 15.4. Market Attractiveness Analysis
    • 15.4.1. By Country
    • 15.4.2. By Drug
    • 15.4.3. By Indication
    • 15.4.4. By Allergan Type
    • 15.4.5. By Distribution Channel
  • 15.5. Market Trends
  • 15.6. Drivers and Restraints - Impact Analysis
  • 15.7. Key Market Participants - Intensity Mapping
  • 15.8. Country Level Analysis & Forecast
    • 15.8.1. Mexico Market Analysis
      • 15.8.1.1. Introduction
      • 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.1.2.1. By Drug
        • 15.8.1.2.2. By Indication
        • 15.8.1.2.3. By Allergan Type
        • 15.8.1.2.4. By Distribution Channel
    • 15.8.2. Brazil Market Analysis
      • 15.8.2.1. Introduction
      • 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.2.2.1. By Drug
        • 15.8.2.2.2. By Indication
        • 15.8.2.2.3. By Allergan Type
        • 15.8.2.2.4. By Distribution Channel
    • 15.8.3. Argentina Market Analysis
      • 15.8.3.1. Introduction
      • 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.3.2.1. By Drug
        • 15.8.3.2.2. By Indication
        • 15.8.3.2.3. By Allergan Type
        • 15.8.3.2.4. By Distribution Channel

16. Europe Market Analysis 2019-2023 and Forecast 2024-2033

  • 16.1. Introduction
  • 16.2. Historical Market Size (US$ Mn) and Volume (Units) Trend Analysis By Market Taxonomy, 2019-2023
  • 16.3. Current and Future Market Size (US$ Mn) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2024-2033
    • 16.3.1. By Country
      • 16.3.1.1. Germany
      • 16.3.1.2. U.K.
      • 16.3.1.3. France
      • 16.3.1.4. Spain
      • 16.3.1.5. Benelux
      • 16.3.1.6. Russia
      • 16.3.1.7. Italy
      • 16.3.1.8. Rest of Europe
    • 16.3.2. By Drug
    • 16.3.3. By Indication
    • 16.3.4. By Allergan Type
    • 16.3.5. By Distribution Channel
  • 16.4. Market Attractiveness Analysis
    • 16.4.1. By Country
    • 16.4.2. By Drug
    • 16.4.3. By Indication
    • 16.4.4. By Allergan Type
    • 16.4.5. By Distribution Channel
  • 16.5. Market Trends
  • 16.6. Drivers and Restraints - Impact Analysis
  • 16.7. Key Market Participants - Intensity Mapping
  • 16.8. Country Level Analysis & Forecast
    • 16.8.1. Germany Market Analysis
      • 16.8.1.1. Introduction
      • 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.1.2.1. By Drug
        • 16.8.1.2.2. By Indication
        • 16.8.1.2.3. By Allergan Type
        • 16.8.1.2.4. By Distribution Channel
    • 16.8.2. U.K. Market Analysis
      • 16.8.2.1. Introduction
      • 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.2.2.1. By Drug
        • 16.8.2.2.2. By Indication
        • 16.8.2.2.3. By Allergan Type
        • 16.8.2.2.4. By Distribution Channel
    • 16.8.3. France Market Analysis
      • 16.8.3.1. Introduction
      • 16.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.3.2.1. By Drug
        • 16.8.3.2.2. By Indication
        • 16.8.3.2.3. By Allergan Type
        • 16.8.3.2.4. By Distribution Channel
    • 16.8.4. Spain Market Analysis
      • 16.8.4.1. Introduction
      • 16.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.4.2.1. By Drug
        • 16.8.4.2.2. By Indication
        • 16.8.4.2.3. By Allergan Type
        • 16.8.4.2.4. By Distribution Channel
    • 16.8.5. BENELUX Market Analysis
      • 16.8.5.1. Introduction
      • 16.8.5.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.5.2.1. By Drug
        • 16.8.5.2.2. By Indication
        • 16.8.5.2.3. By Allergan Type
        • 16.8.5.2.4. By Distribution Channel
    • 16.8.6. Russia Market Analysis
      • 16.8.6.1. Introduction
      • 16.8.6.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.6.2.1. By Drug
        • 16.8.6.2.2. By Indication
        • 16.8.6.2.3. By Allergan Type
        • 16.8.6.2.4. By Distribution Channel
    • 16.8.7. Italy Market Analysis
      • 16.8.7.1. Introduction
      • 16.8.7.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.7.2.1. By Drug
        • 16.8.7.2.2. By Indication
        • 16.8.7.2.3. By Allergan Type
        • 16.8.7.2.4. By Distribution Channel

17. East Asia Market Analysis 2019-2023 and Forecast 2024-2033

  • 17.1. Introduction
  • 17.2. Historical Market Size (US$ Mn) and Volume (Units) Trend Analysis By Market Taxonomy, 2019-2023
  • 17.3. Current and Future Market Size (US$ Mn) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2024-2033
    • 17.3.1. By Country
      • 17.3.1.1. China
      • 17.3.1.2. Japan
      • 17.3.1.3. South Korea
    • 17.3.2. By Drug
    • 17.3.3. By Indication
    • 17.3.4. By Allergan Type
    • 17.3.5. By Distribution Channel
  • 17.4. Market Attractiveness Analysis
    • 17.4.1. By Country
    • 17.4.2. By Drug
    • 17.4.3. By Indication
    • 17.4.4. By Allergan Type
    • 17.4.5. By Distribution Channel
  • 17.5. Market Trends
  • 17.6. Drivers and Restraints - Impact Analysis
  • 17.7. Key Market Participants - Intensity Mapping
  • 17.8. Country Level Analysis & Forecast
    • 17.8.1. China Market Analysis
      • 17.8.1.1. Introduction
      • 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.1.2.1. By Drug
        • 17.8.1.2.2. By Indication
        • 17.8.1.2.3. By Allergan Type
        • 17.8.1.2.4. By Distribution Channel
    • 17.8.2. Japan Market Analysis
      • 17.8.2.1. Introduction
      • 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.2.2.1. By Drug
        • 17.8.2.2.2. By Indication
        • 17.8.2.2.3. By Allergan Type
        • 17.8.2.2.4. By Distribution Channel
    • 17.8.3. South Korea Market Analysis
      • 17.8.3.1. Introduction
      • 17.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.3.2.1. By Drug
        • 17.8.3.2.2. By Indication
        • 17.8.3.2.3. By Allergan Type
        • 17.8.3.2.4. By Distribution Channel

18. South Asia Market Analysis 2019-2023 and Forecast 2024-2033

  • 18.1. Introduction
  • 18.2. Historical Market Size (US$ Mn) and Volume (Units) Trend Analysis By Market Taxonomy, 2019-2023
  • 18.3. Current and Future Market Size (US$ Mn) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2024-2033
    • 18.3.1. By Country
      • 18.3.1.1. India
      • 18.3.1.2. Indonesia
      • 18.3.1.3. Malaysia
      • 18.3.1.4. Thailand
      • 18.3.1.5. Rest of South Asia
    • 18.3.2. By Drug
    • 18.3.3. By Indication
    • 18.3.4. By Allergan Type
    • 18.3.5. By Distribution Channel
  • 18.4. Market Attractiveness Analysis
    • 18.4.1. By Country
    • 18.4.2. By Drug
    • 18.4.3. By Indication
    • 18.4.4. By Allergan Type
    • 18.4.5. By Distribution Channel
  • 18.5. Market Trends
  • 18.6. Drivers and Restraints - Impact Analysis
  • 18.7. Key Market Participants - Intensity Mapping
  • 18.8. Country Level Analysis & Forecast
    • 18.8.1. India Market Analysis
      • 18.8.1.1. Introduction
      • 18.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 18.8.1.2.1. By Drug
        • 18.8.1.2.2. By Indication
        • 18.8.1.2.3. By Allergan Type
        • 18.8.1.2.4. By Distribution Channel
    • 18.8.2. Indonesia Market Analysis
      • 18.8.2.1. Introduction
      • 18.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 18.8.2.2.1. By Drug
        • 18.8.2.2.2. By Indication
        • 18.8.2.2.3. By Allergan Type
        • 18.8.2.2.4. By Distribution Channel
    • 18.8.3. Malaysia Market Analysis
      • 18.8.3.1. Introduction
      • 18.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 18.8.3.2.1. By Drug
        • 18.8.3.2.2. By Indication
        • 18.8.3.2.3. By Allergan Type
        • 18.8.3.2.4. By Distribution Channel
    • 18.8.4. Thailand Market Analysis
      • 18.8.4.1. Introduction
      • 18.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 18.8.4.2.1. By Drug
        • 18.8.4.2.2. By Indication
        • 18.8.4.2.3. By Allergan Type
        • 18.8.4.2.4. By Distribution Channel

19. Oceania Market 2019-2023 and Forecast 2024-2033

  • 19.1. Introduction
  • 19.2. Historical Market Size (US$ Mn) and Volume (Units) Trend Analysis By Market Taxonomy, 2019-2023
  • 19.3. Current and Future Market Size (US$ Mn) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2024-2033
    • 19.3.1. By Country
      • 19.3.1.1. Australia
      • 19.3.1.2. New Zealand
    • 19.3.2. By Drug
    • 19.3.3. By Indication
    • 19.3.4. By Allergan Type
    • 19.3.5. By Distribution Channel
  • 19.4. Market Attractiveness Analysis
    • 19.4.1. By Country
    • 19.4.2. By Drug
    • 19.4.3. By Indication
    • 19.4.4. By Allergan Type
    • 19.4.5. By Distribution Channel
  • 19.5. Market Trends
  • 19.6. Drivers and Restraints - Impact Analysis
  • 19.7. Key Market Participants - Intensity Mapping
  • 19.8. Country Level Analysis & Forecast
    • 19.8.1. Australia Market Analysis
      • 19.8.1.1. Introduction
      • 19.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.1.2.1. By Drug
        • 19.8.1.2.2. By Indication
        • 19.8.1.2.3. By Allergan Type
        • 19.8.1.2.4. By Distribution Channel
    • 19.8.2. New Zealand Market Analysis
      • 19.8.2.1. Introduction
      • 19.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.2.2.1. By Drug
        • 19.8.2.2.2. By Indication
        • 19.8.2.2.3. By Allergan Type
        • 19.8.2.2.4. By Distribution Channel

20. Middle East and Africa (MEA) Market Analysis 2019-2023 and Forecast 2024-2033

  • 20.1. Introduction
  • 20.2. Historical Market Size (US$ Mn) and Volume (Units) Trend Analysis By Market Taxonomy, 2019-2023
  • 20.3. Current and Future Market Size (US$ Mn) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2024-2033
    • 20.3.1. By Country
      • 20.3.1.1. GCC Countries
      • 20.3.1.2. South Africa
      • 20.3.1.3. Turkiye
      • 20.3.1.4. North Africa
      • 20.3.1.5. Rest of MEA
    • 20.3.2. By Drug
    • 20.3.3. By Indication
    • 20.3.4. By Allergan Type
    • 20.3.5. By Distribution Channel
  • 20.4. Market Attractiveness Analysis
    • 20.4.1. By Country
    • 20.4.2. By Drug
    • 20.4.3. By Indication
    • 20.4.4. By Allergan Type
    • 20.4.5. By Distribution Channel
  • 20.5. Market Trends
  • 20.6. Drivers and Restraints - Impact Analysis
  • 20.7. Key Market Participants - Intensity Mapping
  • 20.8. Country Level Analysis & Forecast
    • 20.8.1. GCC Countries Market Analysis
      • 20.8.1.1. Introduction
      • 20.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 20.8.1.2.1. By Drug
        • 20.8.1.2.2. By Indication
        • 20.8.1.2.3. By Allergan Type
        • 20.8.1.2.4. By Distribution Channel
    • 20.8.2. South Africa Market Analysis
      • 20.8.2.1. Introduction
      • 20.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 20.8.2.2.1. By Drug
        • 20.8.2.2.2. By Indication
        • 20.8.2.2.3. By Allergan Type
        • 20.8.2.2.4. By Distribution Channel
    • 20.8.3. Turkiye Market Analysis
      • 20.8.3.1. Introduction
      • 20.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 20.8.3.2.1. By Drug
        • 20.8.3.2.2. By Indication
        • 20.8.3.2.3. By Allergan Type
        • 20.8.3.2.4. By Distribution Channel
    • 20.8.4. North Africa Market Analysis
      • 20.8.4.1. Introduction
      • 20.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 20.8.4.2.1. By Drug
        • 20.8.4.2.2. By Indication
        • 20.8.4.2.3. By Allergan Type
        • 20.8.4.2.4. By Distribution Channel

21. Market Structure Analysis

  • 21.1. Market Analysis by Tier of Companies
  • 21.2. Market Share Analysis of Top Players
  • 21.3. Market Concentration
  • 21.4. Market Presence Analysis

22. Competition Analysis

  • 22.1. Competition Dashboard
  • 22.2. Branding and Promotional Strategies, By Key Players
  • 22.3. Key Development Analysis
  • 22.4. Competition Deep Dive
    • 22.4.1. ALK Abello
      • 22.4.1.1. Overview
      • 22.4.1.2. Product Portfolio
      • 22.4.1.3. Key Financials
      • 22.4.1.4. Sales Footprint
      • 22.4.1.5. SWOT Analysis
      • 22.4.1.6. Strategy Overview
        • 22.4.1.6.1. Marketing Strategy
        • 22.4.1.6.2. Product Strategy
        • 22.4.1.6.3. Channel Strategy
    • 22.4.2. Stallergenes Greer
      • 22.4.2.1. Overview
      • 22.4.2.2. Product Portfolio
      • 22.4.2.3. Key Financials
      • 22.4.2.4. Sales Footprint
      • 22.4.2.5. SWOT Analysis
      • 22.4.2.6. Strategy Overview
        • 22.4.2.6.1. Marketing Strategy
        • 22.4.2.6.2. Product Strategy
        • 22.4.2.6.3. Channel Strategy
    • 22.4.3. Allergy Therapeutics
      • 22.4.3.1. Overview
      • 22.4.3.2. Product Portfolio
      • 22.4.3.3. Key Financials
      • 22.4.3.4. Sales Footprint
      • 22.4.3.5. SWOT Analysis
      • 22.4.3.6. Strategy Overview
        • 22.4.3.6.1. Marketing Strategy
        • 22.4.3.6.2. Product Strategy
        • 22.4.3.6.3. Channel Strategy
    • 22.4.4. Aimmune Therapeutics
      • 22.4.4.1. Overview
      • 22.4.4.2. Product Portfolio
      • 22.4.4.3. Key Financials
      • 22.4.4.4. Sales Footprint
      • 22.4.4.5. SWOT Analysis
      • 22.4.4.6. Strategy Overview
        • 22.4.4.6.1. Marketing Strategy
        • 22.4.4.6.2. Product Strategy
        • 22.4.4.6.3. Channel Strategy
    • 22.4.5. Biomay AG
      • 22.4.5.1. Overview
      • 22.4.5.2. Product Portfolio
      • 22.4.5.3. Key Financials
      • 22.4.5.4. Sales Footprint
      • 22.4.5.5. SWOT Analysis
      • 22.4.5.6. Strategy Overview
        • 22.4.5.6.1. Marketing Strategy
        • 22.4.5.6.2. Product Strategy
        • 22.4.5.6.3. Channel Strategy
    • 22.4.6. HAL Allergy group
      • 22.4.6.1. Overview
      • 22.4.6.2. Product Portfolio
      • 22.4.6.3. Key Financials
      • 22.4.6.4. Sales Footprint
      • 22.4.6.5. SWOT Analysis
      • 22.4.6.6. Strategy Overview
        • 22.4.6.6.1. Marketing Strategy
        • 22.4.6.6.2. Product Strategy
        • 22.4.6.6.3. Channel Strategy
    • 22.4.7. DBV Technologies
      • 22.4.7.1. Overview
      • 22.4.7.2. Product Portfolio
      • 22.4.7.3. Key Financials
      • 22.4.7.4. Sales Footprint
      • 22.4.7.5. SWOT Analysis
      • 22.4.7.6. Strategy Overview
        • 22.4.7.6.1. Marketing Strategy
        • 22.4.7.6.2. Product Strategy
        • 22.4.7.6.3. Channel Strategy
    • 22.4.8. Merck KGaA
      • 22.4.8.1. Overview
      • 22.4.8.2. Product Portfolio
      • 22.4.8.3. Key Financials
      • 22.4.8.4. Sales Footprint
      • 22.4.8.5. SWOT Analysis
      • 22.4.8.6. Strategy Overview
        • 22.4.8.6.1. Marketing Strategy
        • 22.4.8.6.2. Product Strategy
        • 22.4.8.6.3. Channel Strategy
    • 22.4.9. WOLWpharma
      • 22.4.9.1. Overview
      • 22.4.9.2. Product Portfolio
      • 22.4.9.3. Key Financials
      • 22.4.9.4. Sales Footprint
      • 22.4.9.5. SWOT Analysis
      • 22.4.9.6. Strategy Overview
        • 22.4.9.6.1. Marketing Strategy
        • 22.4.9.6.2. Product Strategy
        • 22.4.9.6.3. Channel Strategy

23. Assumptions and Acronyms Used

24. Research Methodology